Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma-Reference-Cited by-同舟云学术

Myeloid cell differentiation-related gene signature for predicting clinical outcome, immune microenvironment, and treatment response in lung adenocarcinoma

Published:2024-07-29 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Wu Di,Liu Yibing,Liu Jian,Ma Li,Tong Xiaoxia

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-68111-5.pdf

Reference45 articles.

1. Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer Statistics, 2021. CA: a cancer journal for clinicians 71, 7–33, https://doi.org/10.3322/caac.21654 (2021).

2. Lortet-Tieulent, J. et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 84, 13–22. https://doi.org/10.1016/j.lungcan.2014.01.009 (2014).

3. Song, Y., Zhang, J., Fang, L. & Liu, W. Prognostic necroptosis-related gene signature aids immunotherapy in lung adenocarcinoma. Front. Genet. 13, 1027741. https://doi.org/10.3389/fgene.2022.1027741 (2022).

4. Rizzo, A. et al. Impact of Proton Pump Inhibitors and Histamine-2-Receptor Antagonists on Non-Small Cell Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis. Cancers (Basel) https://doi.org/10.3390/cancers14061404 (2022).

5. Rizzo, A. Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate. Br. J. Cancer 127, 1381–1382. https://doi.org/10.1038/s41416-022-01929-w (2022).

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Elevated BEAN1 expression correlates with poor prognosis, immune evasion, and chemotherapy resistance in rectal adenocarcinoma;Discover Oncology;2024-09-14